- Investing Ideas
- U.S. Pharmaceuticals & Biotech Undervalued based on future growth
U.S. Pharmaceuticals & Biotech Undervalued based on future growth
Results
14
Companies which can be considered undervalued when accounting for expected future growth (PEG under 0.8)
14 companies
Alkermes
Market Cap: US$4.9b
A biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally.
ALKS
US$28.35
7D
-7.7%
1Y
-18.2%
Indivior Pharmaceuticals
Market Cap: US$4.0b
Engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and related disorders in the United States, Europe, Canada, Australia, and internationally.
INDV
US$32.05
7D
-4.9%
1Y
224.1%
ACADIA Pharmaceuticals
Market Cap: US$4.0b
A biopharmaceutical company, focuses on the development and commercialization of medicines for neurological and rare disease in North America.
ACAD
US$22.40
7D
-9.1%
1Y
27.2%
BioCryst Pharmaceuticals
Market Cap: US$2.1b
A biotechnology company, developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases.
BCRX
US$8.50
7D
-2.9%
1Y
10.5%
Bausch Health Companies
Market Cap: US$2.1b
Operates as a diversified specialty pharmaceutical and medical device company, develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, generic pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health in the United States and internationally.
BHC
US$5.57
7D
-7.8%
1Y
-22.7%
Organon
Market Cap: US$1.8b
Develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally.
OGN
US$6.71
7D
-7.2%
1Y
-54.8%
Collegium Pharmaceutical
Market Cap: US$1.3b
A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.
COLL
US$37.28
7D
-15.7%
1Y
25.1%
Alvotech
Market Cap: US$1.2b
Through its subsidiaries, develops and manufactures biosimilar medicines for patients worldwide.
ALVO
US$4.16
7D
0%
1Y
-62.6%
CorMedix
Market Cap: US$561.0m
A biopharmaceutical company, focuses on developing and commercializing therapeutic products for life-threatening diseases and conditions in the United States.
CRMD
US$6.30
7D
-14.3%
1Y
-33.6%
Zevra Therapeutics
Market Cap: US$502.7m
A commercial-stage company, focuses on addressing unmet needs for the treatment of rare diseases in the United States.
ZVRA
US$8.79
7D
-3.3%
1Y
9.2%
SIGA Technologies
Market Cap: US$456.2m
A commercial-stage pharmaceutical company, focuses on the health security market in the United States.
SIGA
US$6.24
7D
-6.0%
1Y
9.3%
Abeona Therapeutics
Market Cap: US$269.3m
A clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.
ABEO
US$4.87
7D
-6.3%
1Y
-8.1%
Coherus Oncology
Market Cap: US$263.1m
A biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States.
CHRS
US$1.76
7D
4.1%
1Y
76.9%
Earth Science Tech
Market Cap: US$32.6m
Together with its subsidies, focuses on health and wellness industry.
ETST
US$0.12
7D
1.2%
1Y
-17.2%